ArticleSignal transduction and targeted therapy2025
When vaccines reset tumors: SARS-CoV-2 mRNA shots create a transient checkpoint-sensitive state.
Abstract read
In one paragraph
Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Impact of COVID-19 Vaccination on Patients with Non-Small Cell Lung Cancer Receiving First-Line Immune Checkpoint Inhibitor Therapy: Real-World Evidence from Romania.Medicina (Kaunas, Lithuania) · 2026Article
- Impact of Prior mRNA COVID-19 Vaccination on PFS2 in NSCLC Patients Receiving Second-Line Immune Checkpoint Inhibitors: A Real-World Analysis.Journal of clinical medicine · 2026Article
- Machine learning prioritization identifies PANX1 as an inflammation-associated candidate regulator in lung adenocarcinoma.Frontiers in genetics · 2026Article
- DUSP5 contributes to platinum resistance in ovarian cancer: single-cell discovery and functional validation.Frontiers in pharmacology · 2026Article
- Targeting the Neuro-Immune Axis in Next-Generation Oncology: Discovery and Validation of βOncology research · 2026Review
- IL1RAP Is Associated With an Inflammation-Immunity-Related State in Skin Cutaneous Melanoma: Integrative Evidence From Pan-Cancer Data and Melanoma Immunotherapy Cohorts.International journal of genomics · 2026Article
- SLPI is associated with AR-regulated epithelial adaptation and enzalutamide sensitivity in castration-resistant prostate cancer.Frontiers in pharmacology · 2026Article
- Single-Cell and Bulk Transcriptomic Integration Reveals an Adverse SPP1 Inflammatory TAM State and INHBA as a Candidate Biomarker in Non-Small Cell Lung Cancer Immunotherapy.International journal of genomics · 2026Article
- Exposure-aware multi-omics and artificial intelligence for biomarker discovery and precision prevention in diffuse glioma.Frontiers in immunology · 2026Review
- Exposure-shaped immunometabolic networks in chronic liver disease: translating multi-omics and artificial intelligence into preventive biomarkers.Frontiers in immunology · 2026Review
- Decoding the role of macrophage LAP3 in lung cancer - integration of single-cell technologies and machine learning reveals an orchestrating immunometabolic circuit at the tumor-epithelial interface.Frontiers in immunology · 2026Article
- Immune exclusion as a recurrent immune-escape state driving treatment resistance in osteosarcoma: insights from single-cell, spatial, and multi-omics studies.Frontiers in immunology · 2026Review
- The Cellular and Immune Context of YTHDC1 in Hepatocellular Carcinoma: A Single-Cell and Multicohort Study.International journal of genomics · 2026Article
- The evolution of vaccine strategies for colorectal cancer: from conventional approaches to the mRNA era.Frontiers in immunology · 2026Review
- Vaccination-enabled immune readiness for checkpoint blockade.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Hao ChiDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.
Michele CarboneThoracic Oncology Program, University of Hawaii Cancer Center, Honolulu, HI, USA. mcarbone@cc.hawaii.edu.
Youping DengDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA. dengy@hawaii.edu.ORCID http://orcid.org/0000-0002-5951-8213
Funding
AIM-AHEAD Coordinating Center - All Four CoresOT2OD032581 · OD · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI Paul Avillach, Bettina M. Beech · 2021 to 2026
$168.7MUH Hilo COP A&RP20GM103466 · NIGMS · UNIVERSITY OF HAWAII AT MANOA · PI Peter R Hoffmann · 2012 to 2026
$60.3MThe Role of gp120 on Cardiovascular Disease in People Living with HIVU54MD007601 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI Jerris Robert Hedges · 2017 to 2026
$59.5MUrgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)U24MD015970 · NIMHD · MOREHOUSE SCHOOL OF MEDICINE · PI Sandra Perreira Chang, Elizabeth O. Ofili · 2020 to 2026
$20.6MPacific Center for Genome ResearchU54HG013243 · NHGRI · UNIVERSITY OF HAWAII AT MANOA · PI Youping Deng · 2023 to 2026
$10.8MProfiling genome-wide circulating ncRNAs for the early detection of lung cancerR01CA223490 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI DENG, YOUPING · 2018 to 2022
$3.1MCirculating lipid and miRNA markers for early detection of breast cancer among women with abnormal mammogramsR01CA230514 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI DENG, YOUPING · 2019 to 2023
$2.8MPacific Computational Genomics and Data Sciences Research Education ProgramUE5HG013826 · NHGRI · UNIVERSITY OF HAWAII AT MANOA · PI DENG, YOUPING, ZHANG, YIQIANG · 2024 to 2024
$486kFoundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) 1OT2OD032581-02-PP90YFoundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) 1UE5HG013826Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) 3OT2OD032581-01S5-895Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) P20GM103466Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01CA223490Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01CA230514Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) U54HG013243Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) U54MD015970NCI NIH HHS R01 CA223490NCI NIH HHS R01 CA230514NHGRI NIH HHS U54 HG013243NHGRI NIH HHS UE5 HG013826NIGMS NIH HHS P20 GM103466NIH HHS OT2 OD032581NIMHD NIH HHS U24 MD015970NIMHD NIH HHS U54 MD007601
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.